Heart transplantation in Fontan patients across Australia and New Zealand
Heart transplantation in Fontan patients across Australia and New Zealand
复制标题
DOI：
10.1136/heartjnl-2015-308848
复制
发表时间：
2016-07-01
期刊：
影响因子：
5.7
通讯作者：
Konstantinov, Igor E.
中科院分区：
文献类型：
--
作者：
Shi, William Y.;Yong, Matthew S.;Konstantinov, Igor E.
目的Fontan生理学疾病患者最终可能需要心脏移植(HT)。我们在一项全国性的基于人群的多中心研究中确定了高血压的发生率和结局。方法从1990年到2015年，1369名患者接受了Fontan手术，记录在澳大利亚和新西兰Fontan注册中。我们确定了那些接受了HT的人，并分析了他们的结果。我们比较了两个集水区的HT发生率。在第1区(n=721)，患者被转介至国家儿科羟色胺方案或其相关成人方案。在区域2(n=648)，患者被转介到国家儿科HT计划或其他成人HT计划。结果Fontan术后平均随访时间为11+/-8年。20年后Fontan衰竭的生存率为74%+/-3.9%。34例患者接受了高压氧治疗。居住在第1区的患者患高血压的可能性更大(4.0%，29/721比0.8%，5/648，p
Objective Patients with Fontan physiology may eventually require heart transplantation (HT). We determined the rates and outcomes of HT in a national, population-based multicentre study.Methods From 1990 to 2015, 1369 patients underwent the Fontan procedure as recorded in the Australia and New Zealand Fontan Registry. We identified those who underwent HT and analysed their outcomes. We compared rates of HT between two catchment areas. In area 1 (n=721), patients were referred to the national paediatric HT programme or its associated adult programme. In area 2 (n=648), patients were referred to the national paediatric HT programme or one of the other adult HT programmes.Results Mean follow-up time post-Fontan was 11 +/- 8 years. Freedom from Fontan failure was 74%+/- 3.9% at 20 years. HT was performed in 34 patients. Patients living in area 1 were more likely to have HT (4.0%, 29/721 vs 0.8%, 5/648, p